Articles

The No Surprises Act represents a rare bipartisan moment for Congress and a long-needed safeguard for patients that will reorient relationships among payers and providers.

Over a four-part webinar series, Schaeffer Center will bring together experts to discuss how we can move precision medicine from theory to practice.

New in STAT, Dana Goldman and Darius Lakdawalla discuss how the FDA’s recent approval of the first disease modifying therapy aducanumab against Alzheimer’s disease will pave the way for bigger breakthrough.

A Medicaid-Medicare partnership could cover lifesaving hepatitis C medications — and still save $1 to $1.1 billion over 25 years

The Roybal Center for Behavioral Interventions in Aging seeks proposals for pilot projects that involve randomized controlled trials (RCTs).

The relationship between approvals and future innovation is unclear at best. As such, the FDA should continue to base its decisions solely on safety and efficacy, rather than speculative long-term innovation effects.

Jehan Sparks helped design the top-performing “nudge” which resulted in an 11% increase in the rate of flu shot vaccinations.

Targeted therapies accounted for about 90% of new active substance approvals in oncology between 2011 and 2018.

Black and Latino neighborhoods in the 30 most populous U.S. cities had fewer pharmacies than white or diverse neighborhoods in 2007-2015, USC research shows, suggesting that ‘pharmacy deserts’ — like so-called food deserts — may be an overlooked contributor to persistent racial and ethnic health disparities.

Despite a 1979 federal court-ordered settlement that would have pumped millions of dollars into California for Native American health care, the state’s share remains stunningly underfunded by the Indian Health Service, according to a new story from The Center for Health Reporting.